Experts Discuss Non-Responders to CRT and AF Ablation at ESC Scientific Symposium

All-Women EPIC Alliance Panel Discusses Improving Cardiac Resynchronization Therapy and Atrial Fibrillation Ablation at World's Largest Cardiology Congress

ID: 1455201
recent pressrelease next pressrelease

(PresseBox) - in, Germany, 30.08.2016 - EPIC Alliance experts at the European Society of Cardiology (ESC) congress presented original research and real-world clinical evidence on non-responders to cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) ablation today.
The all-women panel of physicians from the EPIC Alliance, an initiative promoting female electrophysiologists (EPs), spoke on how to support patients who do not respond to treatment at the symposium ?Breaking the Non-Response Barrier: CRT and AF Ablation?.
Both CRT and AF ablation can be life-saving, but despite major technological breakthroughs, and a broader understanding of the pathophysiology, the success rates of both procedures plateau at about 70 percent.1,2 The reasons for this remains largely unknown, but ongoing studies such as BIOWOMEN are investigating which patients best respond to CRT therapy.
Dr. Mina Chung, Cleveland Clinic, US, kicked off the symposium with an overview of the latest findings in CRT trials. She was followed by Dr. Gemma Pelargonio, Catholic University of the Sacred Heart, Rome, Italy, who explored using CRT in heart failure patients with ?narrow? QRS complexes. Dr. Claudia Herrera-Siklody, Ludwigsburg Clinic, Germany, discussed strategies to treat persistent AF, and Dr. Isabella Deisenhofer, German Heart Centre, Munich, ended the symposium by weighing the risks and benefits of AF ablation.
?Pushing success rates for CRT and AF ablation will require a greater understanding of the clinical barriers and novel technologies, and this symposium highlighted that significant issue,? commented Dr. Sabine Ernst, Royal Brompton and Harefield Hospital, London, UK, who co-chaired the session. Speaking about the EPIC Alliance she added: ?The EPIC Alliance is a global network of women in EP supporting women to choose EP as a career option and to reach their full potential. One way we can do that is to feature them as speakers at prominent symposia such as the ESC Congress.?


References
1 Daubert C et al. European Heart Journal. July 2016.
2 Bottoni N et al. Europace. 2015, 17.
About the EPIC Alliance
The Electrophysiologist International Community (EPIC) Alliance is a global network of over 200 women EPs and cardiac device specialists. Founded in 2010, its aims to diversify the medical field by promoting women in their professional and personal lives. The alliance fosters peer support, clinical research opportunities, and career development to help women gain leadership positons in their clinics, professional associations and at scientific congresses. BIOTRONIK sponsors EPIC with an educational grant. Register to receive news about upcoming events and scientific sessions.

A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world''s first 4 F compatible stent for treating long lesions; Orsiro, the industry''s first hybrid drug-eluting stent; and the world''s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.
For more information, visit: www.biotronik.com
Twitter: (at)BIOTRONIK_News
LinkedIn: www.linkedin.com/company/biotronik



More information:
http://www.realwire.com/releases/Promise-of-significant-revenue-growth-for-operators-as-Broadband-Forum http://feehour.com/ http://www.realwire.com/releases/ManageEngine-Extends-Self-Service-Analytics-to-IT-Operations-Customer http://www.realwire.com/rele



Keywords (optional):



Company information / Profile:

A global leader in cardio- and endovascular medical technology, BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries. Several million patients have received BIOTRONIK implants designed to save and improve the quality of their lives, or have been treated with BIOTRONIK coronary and peripheral vascular intervention products. Since its development of the first German pacemaker in 1963, BIOTRONIK has engineered many innovations, including Magmaris, the first clinically-proven resorbable magnesium scaffold; BIOTRONIK Home Monitoring®; Pulsar, the world''s first 4 F compatible stent for treating long lesions; Orsiro, the industry''s first hybrid drug-eluting stent; and the world''s first implantable cardioverter defibrillators and heart failure therapy devices with ProMRI® technology.
For more information, visit: www.biotronik.com
Twitter: (at)BIOTRONIK_News
LinkedIn: www.linkedin.com/company/biotronik

PressRelease by

Requests:



PressContact / Agency:



published by: PresseBox
print pressrelease  send to a friend  

Date: 08/30/2016 - 09:26
Language: English
News-ID 1455201
Character count: 5088
Kontakt-Informationen:
Firma: BIOTRONIK
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Rom
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 917

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 354
Register today: 0
Register yesterday: 3
Members online: 0
Guests online: 55


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.